Cedars-sinai medical center joins phase i clinical study of abvc biopharma's medication for treating depression in cancer patients

Fremont, ca, nov. 02, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that the cedars-sinai medical center (csmc, west hollywood ca) institutional review board (irb) has approved their institution joining the phase i study of abv-1601 for treating depression in cancer patients. the principal investigator of the csmc study will be dr. scott a. irwin, md, phd., an eminent professor of psychiatry & behavioral neurosciences.
ABVC Ratings Summary
ABVC Quant Ranking